Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9Y2G1
UPID:
MYRF_HUMAN
Alternative names:
Myelin gene regulatory factor
Alternative UPACC:
Q9Y2G1; O43582; Q9P1Q6
Background:
The Myelin Regulatory Factor, known alternatively as Myelin Gene Regulatory Factor, plays a pivotal role in the central nervous system's (CNS) myelination process. It functions as a precursor to a transcription factor essential for activating CNS myelin genes, such as MBP, MOG, MAG, DUSP15, and PLP1, during oligodendrocyte maturation. This protein's activity is crucial not only for oligodendrocyte differentiation but also for maintaining a mature, viable oligodendrocyte phenotype.
Therapeutic significance:
The Myelin Regulatory Factor is implicated in diseases like Encephalitis/encephalopathy, mild, with reversible myelin vacuolization (MMERV) and Cardiac-urogenital syndrome. Understanding its role could lead to novel therapeutic strategies for these conditions, emphasizing the importance of targeted research in uncovering potential treatments.